Breaking Finance News

H.C. Wainwright announced Summit Therapeutics PLC (NASDAQ:SMMT), bumping up its stock price target to $26.00 today

Boasting a price of $5.78, Summit Therapeutics PLC (NASDAQ:SMMT) traded 12.00% lower on the day. With the last stock price down 26.49% relative to the two hundred day moving average, compared with the Standard & Poor’s 500 Index which has fallen -0.01% over the same time. SMMT has been tracking to a 50-day moving average of $6.74 and 200-day average of $7.48. Trade volume was was up over the average, with 21,721 shares of SMMT changing hands over the typical 4,155 shares.

Stating a possible upside of 3.50%, H.C. Wainwright bumped the price target of Summit Therapeutics PLC (NASDAQ:SMMT) to $26

On 9/14/2016, Zacks Investment Research released a statement on Summit Therapeutics PLC(NASDAQ:SMMT) upped the target price from $0.00 to $7.00 that suggested an upside of 0.12%.

Performance Graph:

Summit Therapeutics PLC (NASDAQ:SMMT)

A total of 4 brokerages have issued a ratings update on the company. Zero rate the company a strong buy, 0 rate the stock a buy, 0 analysts rate the company a hold, 0 rate the company to underperform, and finally 0 firmsrate the stock as sell with a consensus target price of $22.00

Summit Therapeutics PLC has a 52 week low of $4.26 and a 52 week high of $12.78 and has a market capitalization of $0.0.

Brief Synopsis On Summit Therapeutics PLC (NASDAQ:SMMT)

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, and which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.